First Trust Exchange-Traded Fund III First Trust SMID Growth Strength ETF FSGS 深 滬
等待開盤 12-16 09:30:00 美东时间
30.9128
-0.143
-0.46%
華盛通- 最 高31.0273
- 今 開30.98
- 成交量 1020股
- 最 低 30.9128
- 昨 收 31.0554
- 總市值 3091.28万
- 52周最高 31.8604
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 24.39
- 委 比 0.00%
- 總股本 100.00万
- 歷史最高 32.5669
- 量 比 1.97
- 振 幅 0.37%
- 歷史最低 9.9631
- 每 手 1
- 風險率 1.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akebia Therapeutics Establishes Rare Kidney Disease Pipeline With AKB-097 Acquisition From Q32 Bio And Praliciguat Candidate
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 BioPhase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indicationsPhase 2 trial
12-01 20:09
Processa Pharma's Abstract, "Adaptive Phase 2/3 Study For PCS499 (499) In Patients With Focal Segmental Glomerulosclerosis (FSGS)", Accepted For Presentation At ASN Kidney Week 2025
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its
11-05 22:16
Travere Therapeutics To Present 11 Abstracts, Including A Late-Breaking Poster At American Society Of Nephrology Kidney Week 2025 In Houston, TX November 6-9 Highlights Including Data Duplex Study Showing More Filspari-Treated Patients Achieved Proteinuria Below 0.7 G/g Compared With Irbesartan, Indicating Reduced Kidney Failure Risk In FSGS
Late-breaking poster from DUPLEX Study shows more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan, correlating with reduced kidney failure risk in FSGSData
10-17 21:09
Travere Shares Are Trading Higher Wednesday: What's Going On?
Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday...
09-11 03:52
Travere Therapeutics Announces FDA Drops Advisory Committee For FILSPARI sNDA In FSGS; PDUFA Target Date Set For January 13, 2026
Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for
09-10 19:03
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
08-29 00:40
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings)
6 analysts have shared their evaluations of Travere Therapeutics (NASDAQ:TVTX) ...
08-28 20:00
ZyVersa Highlights Review Of 172 Studies Linking Lipotoxicity To DKD Progression; Supports Therapeutic Targeting Of Lipid Metabolic Reprogramming
Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression.Earlier data by Kanbay et al (Eur
08-14 19:58
Earnings Preview: Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) is gearing up to announce its quarterly earn...
08-06 03:10
ZyVersa Therapeutics Releases Mid-Year Shareholder Letter Highlighting Recent Corporate Developments And R&D Progress Including Closing Two Financial Transactions Providing Access To $12M In Capital
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have
07-21 20:04
